Table 2.
Cohort characteristics.
| Variable | Acute MI group (N = 49) | Stable CAD group (N = 15) | p-Value |
|---|---|---|---|
| Age (mean ± SD) in years | 58.6 ± 14.4 | 61.3 ± 8.9 | 0.49 |
| Males (%) | 65.3 | 53.3 | 0.54 |
| Caucasian race (%) | 77.6 | 93.3 | 0.09 |
| Current smoker (%) | 53.1 | 20.0 | 0.04 |
| Former smoker (%) | 26.5 | 60.0 | 0.04 |
| Currently consumes alcohol (%) | 32.7 | 46.7 | 0.37 |
| History of dyslipidemia (%) | 46.9 | 86.7 | 0.01 |
| History of diabetes mellitus (%) | 16.3 | 46.7 | 0.03 |
| History of hypertension (%) | 61.2 | 93.3 | 0.06 |
| History of atherosclerosis (%) (MI, CAD, PCI, CABG) | 38.8 | 100.0 | <0.0001 |
| History of congestive heart failure (%) | 8.2 | 6.7 | 1.00 |
| History of chronic renal failure (%) | 8.2 | 0.0 | 0.28 |
| History of stroke (%) | 10.2 | 0.0 | 0.33 |
| HR at time of presentation (mean ± SD) | 84.9 ± 25.0 | 65.9 ± 9.6 | <0.0001 |
| MAP at time of presentation (mean ± SD) | 102.8 ± 24.7 | 91.4 ± 14.3 | 0.09 |
| BMI at time of presentation (mean ± SD) | 27.5 ± 7.24 | 33 ± 7.08 | 0.02 |
| Time (hours) elapsed presentation to T0 (median ± IQR, range) | 3.5 ± 16.0, 36 | 2.0 ± 1.0, 3 | 0.21b |
| Glucose at baseline (mean ± SD, range) | 142.1 ± 56.5, 285 | 131.6 ± 30.6, 107 | 0.35a |
| Creatinine at baseline (mean ± SD, range) | 1.13 ± 0.79, 4.34 | 0.92 ± 0.17, 0.66 | 0.10a |
| ST elevation on EKG at baseline | 63.3 | 0.0 | <0.0001 |
| One vessel with ≥50% coronary stenosis on enrollment angiogram | 79.6 | 66.7 | 0.31 |
| Aspirin use at time of enrollment (%) | 89.8 | 86.7 | 0.66 |
| P2Y12 inhibitors use at enrollment (%) | 53.1 | 50.0 | 0.77 |
aWelch’s t-test.
bWilcoxon rank-sum test.
MI, myocardial infarction; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; BMI, body mass index.